At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
In Brief
A Phase 4 clinical trial evaluating Topotecan, Fludarabine, and 1 other intervention for Acute Myeloid Leukemia. Completed, enrolled 47 participants across 16 sites.
Detailed Summary
The study is designed with drugs used frequently in the treatment of AML, but with a new combination less toxic,and effective in AML multidrug resistant. Justification: * The AML patients with primary resistance or relapsed in the first 12 months after CR, have second line chemotherapy low response rate . * These patients with AML with primary resistance or relapse, that reach remission after a rescue treatment, have an interval free survival and a global survival very short * Probably the resistance to the treatments is in relation to different forms expression of the MDR. * Complete remission is considered valid evaluation, because every patient who should obtain a CR can be considered to be eligible for a possible curative treatment: Ara-C administration to high doses or the TPH treatment